The CEO's large Form 144 filing (46x the recent insider sell average) signals potential bearish sentiment from management. Monitor for actual sales on Form 4 and any subsequent filings (e.g., earnings, pipeline updates) that could explain the timing. The stock may face near-term selling pressure.
Price Chart
Executive Summary
Sanj K. Patel, CEO of Kiniksa Pharmaceuticals, filed a Form 144 to sell 344,591 Class A Ordinary Shares, valued at approximately $17.8 million. This represents a significant insider sale by the CEO, signaling potential intent to monetize equity ahead of any upcoming catalysts.
Key Facts
- Sanj K. Patel (CEO) filed Form 144 to sell 344,591 Class A Ordinary Shares.
- Estimated aggregate value of the proposed sale is $17,780,309.
- Shares are held at Charles Schwab & Co., Inc. and are to be sold on NASDAQ.
- The sale is related to an employee stock option exercise and broker payment for cashless exercise.
- Filing date: April 28, 2026; the options may be sold over various dates.
- Market cap of KNSA is approximately $3.4B, making this sale about 0.5% of market cap.
- Recent insider activity (30d) shows 2 sells totaling $389K, making this sale ~46x larger than the recent average.
Financial Impact
Proposed sale of ~$17.8M in shares by CEO, representing ~0.5% of market cap.
Risk Factors
- CEO selling a large block could indicate lack of confidence in near-term prospects.
- Potential overhang from the proposed sale may pressure the stock price.
- The sale is tied to option exercise, but the magnitude is notable relative to recent insider activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001921094-26-000422 |
| Document: 0001921094-26-000422-index.html | 0001921094-26-000422 |
| Document: 0001921094-26-000422.txt | 0001921094-26-000422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $76.00 | awaiting T+60 | — | $72.98 (−3.97%) |
Oct 27, 2026 today | Press Release | $75.00 | awaiting T+60 | — | $72.98 (−2.69%) |
Oct 22, 2026 5d ago | 8-K | $76.73 | awaiting T+60 | — | $72.98 (−4.89%) |
Oct 22, 2026 5d ago | Press Release | $80.79 | awaiting T+60 | — | $72.98 (−9.67%) |
Sep 3, 2026 7w ago | 144 | $77.91 | awaiting T+60 | — | $72.98 (−6.33%) |
Jul 28, 2026 13w ago | 8-K | $79.44 $79.70 | ▲ +0.33% | ▼ −4.02% | $72.98 (−8.13%) |
Jul 28, 2026 13w ago | Press Release | $79.44 $79.70 | ▲ +0.33% | ▼ −4.02% | $72.98 (−8.13%) |
May 26, 2026 22w ago | 8-K | $51.84 $78.47 | ▲ +51.37% | ▲ +49.49% | $72.98 (+40.78%) |
May 1, 2026 25w ago | 8-K | $57.62 $80.92 | ▲ +40.44% | ▲ +38.58% | $72.98 (+26.66%) |
Apr 28, 2026 26w ago | 144 | $52.99 $62.84 | ▼ −18.59% | ▼ −14.48% | $72.98 (−37.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers